{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:28:01Z","timestamp":1793384881473,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Wellcome Trust to the Kenya Major Overseas Programme","award":["203077"],"award-info":[{"award-number":["203077"]}]},{"name":"Wellcome Trust to the Kenya Major Overseas Programme","award":["203077"],"award-info":[{"award-number":["203077"]}]},{"name":"Wellcome Trust to the Kenya Major Overseas Programme","award":["203077"],"award-info":[{"award-number":["203077"]}]},{"name":"Wellcome Trust to the Kenya Major Overseas Programme","award":["203077"],"award-info":[{"award-number":["203077"]}]},{"name":"Wellcome Trust to the Kenya Major Overseas Programme","award":["203077"],"award-info":[{"award-number":["203077"]}]},{"name":"Wellcome Trust to the Kenya Major Overseas Programme","award":["203077"],"award-info":[{"award-number":["203077"]}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","award":["INV-036442"],"award-info":[{"award-number":["INV-036442"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","award":["INV-036442"],"award-info":[{"award-number":["INV-036442"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","award":["INV-036442"],"award-info":[{"award-number":["INV-036442"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","award":["INV-036442"],"award-info":[{"award-number":["INV-036442"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["103602 and 212176"],"award-info":[{"award-number":["103602 and 212176"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Recent reports from East African countries indicate the emergence and spread of artemisinin partial resistance (ART-R), posing a significant threat to malaria control efforts in the region. The presence of critical\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    kelch13 (k13) resistance markers, including\n                    <jats:italic>C469Y<\/jats:italic>\n                    ,\n                    <jats:italic>P553L<\/jats:italic>\n                    and\n                    <jats:italic>A675V<\/jats:italic>\n                    , have been detected in Kenya, although their clinical significance remains unclear. This highlights an urgent need to closely monitor the prevalence of these mutations. A total of 24,227 dried blood spot (DBS) samples were collected from 82 primary schools across eight counties in Western Kenya during repeated cross-sectional surveys conducted in 2019 (\n                    <jats:italic>n<\/jats:italic>\n                    = 8,111), 2022 (\n                    <jats:italic>n<\/jats:italic>\n                    = 8,086), and 2023 (\n                    <jats:italic>n<\/jats:italic>\n                    = 8,200). Initial screening was performed using a rapid diagnostic test (RDT), and DNA extraction was conducted on RDT-positive samples. These samples were further analyzed using a\n                    <jats:italic>Pf<\/jats:italic>\n                    18s qPCR assay to quantify the\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    DNA. Amplicons from malaria-positive samples were sequenced using a previously established amplicon deep sequencing pipeline to analyze mutations in\n                    <jats:italic>Pfk13<\/jats:italic>\n                    . A total of 500, 920 and 1058 samples from 2019, 2022, and 2023, respectively were successfully processed, enabling a temporal assessment of the changes in k13 mutations in the region. Four mutations that have previously been associated with artemisinin resistance were found. The A675V mutation was the most prevalent, being found in all 8 counties. It was absent in 2019 and increased from 0.9% in 2022 to 5% in 2023. In contrast, the C469Y mutation declined from 4% in 2022 to 1% in 2023, maintaining a presence in 3 counties. The P553L mutation was only detected in 2022 in 1.2% of the samples across 5 counties. The R561H mutation was not detected in 2019 and 2022 but emerged at a low frequency (0.5%) in 2023 in 2 counties. Siaya and Kisumu were the only counties with all 4 validated mutations between 2022 and 2023. The rising prevalence and geographical presence of the A675V mutation and the new detection of R561H in 2023 highlights the critical need for robust molecular surveillance systems to track the frequency and geographic spread of resistance markers. School-based sampling presents a practical and scalable approach for molecular surveillance, providing early warning signals for potential resistance hotspots. Additionally, the detection of the four WHO validated\n                    <jats:italic>Pfk13<\/jats:italic>\n                    artemisinin resistance mutations in Western Kenya underscores the urgency of conducting regular Therapeutic Efficacy Studies (TES) to assess the continued efficacy of frontline antimalarial treatments. Integrating molecular surveillance with TES will generate important data to inform national treatment policies and support the long-term effectiveness of malaria control strategies in Kenya.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-22286-7","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:40:44Z","timestamp":1762159244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Serial cross-sectional school surveys identifies C469Y, P553L, R561H and A675V kelch 13 mutations associated with artemisinin resistance in Western Kenya"],"prefix":"10.1038","volume":"15","author":[{"given":"Victor","family":"Osoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Wamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses M.","family":"Musau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Magudha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Ndwiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Gichuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collins","family":"Okoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiplagat","family":"Rosebella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammy","family":"Mahugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Aricha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Kandie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kibor","family":"Keitany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Kepha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Mwandawiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bejon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Isabella","family":"Ochola-Oyier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"22286_CR1","doi-asserted-by":"publisher","DOI":"10.21203\/RS.3.RS-5080885\/V1","author":"V Osoti","year":"2024","unstructured":"Osoti, V. et al. Detection of Low-Frequency Artemisinin resistance mutations C469Y, P553L and A675V in asymptomatic primary school children in Kenya. Oct https:\/\/doi.org\/10.21203\/RS.3.RS-5080885\/V1 (2024).","journal-title":"Oct"},{"key":"22286_CR2","unstructured":"WHO, World malaria World malaria report report. [Online]. (2024). Available: https:\/\/www.wipo.int\/amc\/en\/mediation\/https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023"},{"key":"22286_CR3","doi-asserted-by":"publisher","unstructured":"Bwire, G. M., Ngasala, B., Mikomangwa, W. P., Kilonzi, M. & Kamuhabwa, A. A. R. Detection of mutations associated with Artemisinin resistance at k13-propeller gene and a near complete return of chloroquine susceptible falciparum malaria in Southeast of Tanzania. Sci. Rep. 10 (1). https:\/\/doi.org\/10.1038\/s41598-020-60549-7 (Dec. 2020).","DOI":"10.1038\/s41598-020-60549-7"},{"issue":"8","key":"22286_CR4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/nejmoa2211803","volume":"389","author":"MD Conrad","year":"2023","unstructured":"Conrad, M. D. et al. Evolution of partial resistance to artemisinins in malaria parasites in Uganda. N Engl. J. Med. 389 (8), 722\u2013732. https:\/\/doi.org\/10.1056\/nejmoa2211803 (2023).","journal-title":"N Engl. J. Med."},{"key":"22286_CR5","doi-asserted-by":"publisher","unstructured":"Van Loon, W. et al. Escalating Plasmodium falciparum K13 marker prevalence indicative of artemisinin resistance in southernRwanda. Antimicrob.Agents Chemother. 68. https:\/\/doi.org\/10.1128\/aac.01299-23 (2024).","DOI":"10.1128\/aac.01299-23"},{"issue":"13","key":"22286_CR6","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/nejmoa2210956","volume":"389","author":"S Mihreteab","year":"2023","unstructured":"Mihreteab, S. et al. Increasing prevalence of Artemisinin-Resistant HRP2-Negative malaria in Eritrea. N Engl. J. Med. 389 (13), 1191\u20131202. https:\/\/doi.org\/10.1056\/nejmoa2210956 (2023).","journal-title":"N Engl. J. Med."},{"key":"22286_CR7","doi-asserted-by":"publisher","unstructured":"Jeang, B. et al. Molecular surveillance of Kelch 13 polymorphisms in plasmodium falciparum isolates from Kenya and Ethiopia. Malar. J. 23 (1), 36. https:\/\/doi.org\/10.1186\/S12936-023-04812-Y (Dec. 2024).","DOI":"10.1186\/S12936-023-04812-Y"},{"key":"22286_CR8","doi-asserted-by":"publisher","DOI":"10.21203\/RS.3.RS-4538408\/V1","author":"M Makau","year":"2024","unstructured":"Makau, M. et al. Evidence of partial Artemisinin resistance in malaria endemic lake Region, Busia County, Western, Kenya. Jul https:\/\/doi.org\/10.21203\/RS.3.RS-4538408\/V1 (2024).","journal-title":"Jul"},{"key":"22286_CR9","doi-asserted-by":"publisher","unstructured":"Osoti, V. et al. Detection of low frequency artemisinin resistance mutations, C469Y, P553L and A675V, and fixed antifolate resistance mutations in asymptomatic primary school children in Kenya, BMC Infect. Dis. vol. 25, no. 1, pp. 1\u201310, Jan. 2025, (2025). https:\/\/doi.org\/10.1186\/S12879-025-10462-Z","DOI":"10.1186\/S12879-025-10462-Z"},{"key":"22286_CR10","doi-asserted-by":"publisher","unstructured":"van Loon, W. et al. Detection of Artemisinin Resistance Marker Kelch-13 469Y in Plasmodium falciparum, South Kivu, Democratic Republic of the Congo, Am. J. Trop. Med. Hyg., vol. 110, no. 4, pp. 653\u2013655, 2024, (2022). https:\/\/doi.org\/10.4269\/ajtmh.23-0740","DOI":"10.4269\/ajtmh.23-0740"},{"key":"22286_CR11","doi-asserted-by":"publisher","unstructured":"Mesia Kahunu, G. et al. Identification of the PfK13 mutations R561H and P441L in the Democratic Republic of congo. Int. J. Infect. Dis. 139, 41\u201349. https:\/\/doi.org\/10.1016\/J.IJID.2023.11.026 (Feb. 2024).","DOI":"10.1016\/J.IJID.2023.11.026"},{"key":"22286_CR12","doi-asserted-by":"publisher","unstructured":"Martin, A. C. et al. Emergence and Rising Prevalence of Artemisinin Partial Resistance Marker Kelch13 P441L in a Low MalariaTransmission Setting in Southern Zambia. J. Infect. Dis.  https:\/\/doi.org\/10.1093\/INFDIS\/JIAF188 (2025).","DOI":"10.1093\/INFDIS\/JIAF188"},{"key":"22286_CR13","doi-asserted-by":"publisher","unstructured":"Noedl, H. et al. Dec., Evidence of artemisinin-resistant malaria in western Cambodia., N. Engl. J. Med., vol. 359, no. 24, pp. 2619\u201320, (2008). https:\/\/doi.org\/10.1056\/NEJMc0805011","DOI":"10.1056\/NEJMc0805011"},{"key":"22286_CR14","doi-asserted-by":"publisher","unstructured":"Dondorp, A. M. et al. Jul., Artemisinin Resistance in Plasmodium falciparum Malaria, N. Engl. J. Med., vol. 361, no. 5, pp. 455\u2013467, (2009). https:\/\/doi.org\/10.1056\/nejmoa0808859","DOI":"10.1056\/nejmoa0808859"},{"key":"22286_CR15","doi-asserted-by":"publisher","unstructured":"Ashley, E. A. et al. Jul., Spread of Artemisinin Resistance in Plasmodium falciparum Malaria, N. Engl. J. Med., vol. 371, no. 5, pp. 411\u2013423, (2014). https:\/\/doi.org\/10.1056\/NEJMoa1314981","DOI":"10.1056\/NEJMoa1314981"},{"issue":"5","key":"22286_CR16","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/infdis\/jiu491","volume":"211","author":"S Takala-Harrison","year":"2015","unstructured":"Takala-Harrison, S. et al. Independent emergence of Artemisinin resistance mutations among plasmodium falciparum in Southeast Asia. J. Infect. Dis. 211 (5), 670\u2013679. https:\/\/doi.org\/10.1093\/infdis\/jiu491 (2015).","journal-title":"J. Infect. Dis."},{"key":"22286_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1005-2","author":"A Uwimana","year":"2020","unstructured":"Uwimana, A. et al. Emergence and clonal expansion of in vitro artemisinin-resistant plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-020-1005-2 (2020).","journal-title":"Nat. Med."},{"key":"22286_CR18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/nejmoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala, B. et al. Evidence of Artemisinin-Resistant malaria in Africa. N Engl. J. Med. 385, 1163\u20131171. https:\/\/doi.org\/10.1056\/nejmoa2101746 (2021).","journal-title":"N Engl. J. Med."},{"issue":"11","key":"22286_CR19","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1473-3099(24)00362-1","volume":"24","author":"DS Ishengoma","year":"2024","unstructured":"Ishengoma, D. S. et al. Evidence of Artemisinin partial resistance in Northwestern tanzania: clinical and molecular markers of resistance. Lancet Infect. Dis. 24 (11), 1225\u20131233. https:\/\/doi.org\/10.1016\/S1473-3099(24)00362-1 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"22286_CR20","unstructured":"Juliano, J. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice., (2023)."},{"key":"22286_CR21","doi-asserted-by":"publisher","unstructured":"van Loon, W. et al. Escalating plasmodium falciparum K13 marker prevalence indicative of Artemisinin resistance in Southern Rwanda. Antimicrob. Agents Chemother. 68 (1). https:\/\/doi.org\/10.1128\/AAC.01299-23 (Jan. 2024).","DOI":"10.1128\/AAC.01299-23"},{"key":"22286_CR22","doi-asserted-by":"publisher","unstructured":"Ariey, F. et al. A molecular marker of artemisinin-resistant plasmodium falciparum malaria. Nature 505 (7481), 50\u201355. https:\/\/doi.org\/10.1038\/nature12876 (Jan. 2014).","DOI":"10.1038\/nature12876"},{"issue":"5","key":"22286_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjgh-2018-000999","volume":"3","author":"LC Okell","year":"2018","unstructured":"Okell, L. C. et al. Emerging implications of policies on malaria treatment: genetic changes in the Pfmdr-1 gene affecting susceptibility to artemether\u2013lumefantrine and artesunate\u2013amodiaquine in Africa. BMJ Glob Heal. 3 (5), 1\u201312. https:\/\/doi.org\/10.1136\/bmjgh-2018-000999 (2018).","journal-title":"BMJ Glob Heal"},{"key":"22286_CR24","doi-asserted-by":"publisher","unstructured":"Alegana, V. A. et al. Dec., Plasmodium falciparum parasite prevalence in East Africa: Updating data for malaria stratification, PLOS Glob. Public Heal., vol. 1, no. 12, p. e0000014, (2021). https:\/\/doi.org\/10.1371\/JOURNAL.PGPH.0000014","DOI":"10.1371\/JOURNAL.PGPH.0000014"},{"key":"22286_CR25","doi-asserted-by":"publisher","unstructured":"Osoti, V. et al. Targeted amplicon deep sequencing for monitoring antimalarial resistance markers in Western Kenya. Antimicrob. Agents Chemother. 66 (4). https:\/\/doi.org\/10.1128\/aac.01945-21 (Apr. 2022).","DOI":"10.1128\/aac.01945-21"},{"key":"22286_CR26","doi-asserted-by":"publisher","unstructured":"Asua, V. et al. Mar., Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance across Uganda, J. Infect. Dis., vol. 223, no. 6, pp. 985\u2013994, (2021). https:\/\/doi.org\/10.1093\/infdis\/jiaa687","DOI":"10.1093\/infdis\/jiaa687"},{"key":"22286_CR27","doi-asserted-by":"publisher","unstructured":"Juliano, J. J. et al. Prevalence of mutations associated with Artemisinin partial resistance and sulfadoxine\u2013pyrimethamine resistance in 13 regions in Tanzania in 2021: a cross-sectional survey. Lancet Microbe. 5 (10), 100920. https:\/\/doi.org\/10.1016\/S2666-5247(24)00160-5 (Oct. 2024).","DOI":"10.1016\/S2666-5247(24)00160-5"},{"key":"22286_CR28","doi-asserted-by":"crossref","unstructured":"Bdoulaye, A. D. et al. A molecular marker for chloroquine-resistant falciparum malaria a molecular marker for chloroquine-resistant falciparum malaria abstract Background Chloroquine-resistant Plasmodium fal, N Engl J Med, vol. 344, no. 4, Accessed: Feb. 20, 2025. [Online]. Available: www.nejm.org (2001).","DOI":"10.1056\/NEJM200101253440411"},{"key":"22286_CR29","doi-asserted-by":"crossref","unstructured":"Wongsrichanalai, C., Pickard, A. L., Wernsdorfer, W. H. & Meshnick, S. R. Reviews Epidemiology of drug-resistant malaria, vol. 2, pp. 209\u2013218, (2002).","DOI":"10.1016\/S1473-3099(02)00239-6"},{"issue":"1","key":"22286_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1054\/DRUP.1998.0060","volume":"2","author":"T Triglia","year":"1999","unstructured":"Triglia, T. & Cowman, A. F. The mechanism of resistance to Sulfa drugs in plasmodium falciparum. Drug Resist. Updat. 2 (1), 15\u201319. https:\/\/doi.org\/10.1054\/DRUP.1998.0060 (1999).","journal-title":"Drug Resist. Updat"},{"issue":"6906","key":"22286_CR31","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature01097","volume":"419","author":"MJ Gardner","year":"2002","unstructured":"Gardner, M. J. et al. Genome sequence of the human malaria parasite plasmodium falciparum. Nature 419 (6906), 498\u2013511. https:\/\/doi.org\/10.1038\/nature01097 (2002).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22286-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22286-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22286-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:02:13Z","timestamp":1762203733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22286-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22286"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22286-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6890493\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki. Ethical approval was sourced from the Kenya Medical Research Institute (KEMRI) and National Ethics Review Committee (number KEMRI\/SERU\/ESACIPAC\/11\/3822). The student\u2019s parents or guardians provided informed consent while each child assented. Additional approval was provided by the county health and education authorities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"38303"}}